You are here

CCAB announces creation of new brain cancer therapeutic company, Empirica Therapeutics, as part of its strategy to advance new early-stage life sciences companies

TORONTO, Feb. 20, 2019 (GLOBE NEWSWIRE) -- The Centre for the Commercialization of Antibodies and Biologics (CCAB) today announced a license agreement with Empirica Therapeutics Inc. aimed at developing new treatments for one of the deadliest forms of brain cancer, glioblastoma.
Wednesday, February 20, 2019 - 10:30